AstraZeneca Teams with Broad on Antibacterial, Antiviral Drug Research

· TGI - Intelligence, TGI - Pathogens
Authors

Broad Institute has expertise in bacterial genomics and biochemistry and they have chemical library of about 100,000 customized molecules known as Diversity-Oriented Synthesis compounds.

Now the new development is AstraZeneca and the Broad Institute will collaborate on identifying new compounds that target bacterial and viral infections.

In a joint statement they said that the library is “designed to contain molecular shapes and structures not found anywhere else that can hit even the most challenging biological targets”.

 

 

 

Under the collaboration, screening and hit-to-lead efforts will be conducted at the Broad, while AstraZeneca will optimize, develop, and commercialize potential compounds.

They strongly hope and believe that this new and collaborative approaches between the two sectors will help speed the discovery and development of new treatments, particularly for antibiotic-resistant infections.

source: genomeweb

 

 

 

 

 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: